Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. INSP
stocks logo

INSP

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
262.46M
+9.49%
0.677
-41.12%
213.40M
+6%
0.149
+48.63%
242.65M
+11.78%
0.364
-19.2%
Estimates Revision
The market is revising Upward the revenue expectations for Inspire Medical Systems, Inc. (INSP) for FY2025, with the revenue forecasts being adjusted by 0.11% over the past three months. During the same period, the stock price has changed by 61.96%.
Revenue Estimates for FY2025
Revise Upward
up Image
+0.11%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+53.31%
In Past 3 Month
Stock Price
Go Up
up Image
+61.96%
In Past 3 Month
Wall Street analysts forecast INSP stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for INSP is 115.58 USD with a low forecast of 82.00 USD and a high forecast of 180.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
14 Analyst Rating
Wall Street analysts forecast INSP stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for INSP is 115.58 USD with a low forecast of 82.00 USD and a high forecast of 180.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Buy
5 Hold
0 Sell
Moderate Buy
Current: 140.030
sliders
Low
82.00
Averages
115.58
High
180.00
Current: 140.030
sliders
Low
82.00
Averages
115.58
High
180.00
Morgan Stanley
Overweight -> Equal Weight
downgrade
$130
2025-12-02
New
Reason
Morgan Stanley
Price Target
$130
2025-12-02
New
downgrade
Overweight -> Equal Weight
Reason
Morgan Stanley downgraded Inspire Medical to Equal Weight from Overweight with a $130 price target.
Wolfe Research
Peer Perform
to
Outperform
upgrade
$180
2025-11-25
Reason
Wolfe Research
Price Target
$180
2025-11-25
upgrade
Peer Perform
to
Outperform
Reason
Wolfe Research upgraded Inspire Medical to Outperform from Peer Perform with an $180 price target. The firm says the "surprise" 50% Medicare reimbursement raise "pumps oxygen" into the stock's bull case. Inspire has already de-risked 2026 estimates, its 2025 "launch snafus" are nearly behind the company and it has "long list of potential acquirers," the analyst tells investors in a research note. Paying revenue-times estimated 2026 revenue, which the price target represents, it "not crazy" for a SMID-cap medical technology stock, contends Wolfe. Inspire Medical shares in premarket trading are up $1.71 to $119.00.
Truist
Hold
to
Buy
upgrade
$128 -> $165
2025-11-25
Reason
Truist
Price Target
$128 -> $165
2025-11-25
upgrade
Hold
to
Buy
Reason
Truist upgraded Inspire Medical to Buy from Hold with a price target of $165, up from $128.
Truist
Hold
to
Buy
upgrade
$128 -> $165
2025-11-25
Reason
Truist
Price Target
$128 -> $165
2025-11-25
upgrade
Hold
to
Buy
Reason
Truist upgraded Inspire Medical to Buy from Hold with a price target of $165, up from $128, following the "surprise" positive reimbursement OPPS "upcode." The firm didn't upgrade the shares initially as it was unsure if the news was "too good to be true" or a loophole that might reverse, but after conversations with a reimbursement specialist the firm thinks it is likely that Inspire will and should increase its average selling price "considerably" and that even if code changes were to be required down the road, an elevated selling price and reimbursement situation is likely here to stay, regardless.
Wolfe Research
Peer Perform
to
Outperform
upgrade
$180
2025-11-25
Reason
Wolfe Research
Price Target
$180
2025-11-25
upgrade
Peer Perform
to
Outperform
Reason
Wolfe Research upgraded Inspire Medical to Outperform from Peer Perform with an $180 price target. The firm says the company's "surprise" reimbursement increase adds conviction in the bull case for the shares. Wolfe's price target represents 5-times Inspire's estimated 2026 revenue.
Nephron Research
Hold
to
Buy
upgrade
2025-11-24
Reason
Nephron Research
Price Target
2025-11-24
upgrade
Hold
to
Buy
Reason
Nephron Research upgraded Inspire Medical to Buy from Hold.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Inspire Medical Systems Inc (INSP.N) is 85.42, compared to its 5-year average forward P/E of 5.27. For a more detailed relative valuation and DCF analysis to assess Inspire Medical Systems Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
5.27
Current PE
85.42
Overvalued PE
227.73
Undervalued PE
-217.18

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-31.42
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
141.08
Undervalued EV/EBITDA
-203.92

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
12.35
Current PS
0.00
Overvalued PS
19.98
Undervalued PS
4.72
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

INSP News & Events

Events Timeline

(ET)
2025-11-24
12:00:22
Inspire Medical Shares Surge by 28.3%
select
2025-11-24
10:00:03
Inspire Medical Shares Surge by 25.4%
select
2025-11-17 (ET)
2025-11-17
18:43:44
Inspire Medical anticipates $90M-$100M tax benefit for fiscal year 2025.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
7.0
05:21 AMGlobenewswire
Inspire Medical Systems Faces Class Action Lawsuit Over Alleged Securities Fraud
  • Class Action Initiation: Levi & Korsinsky has filed a class action lawsuit against Inspire Medical Systems to recover losses for investors affected between August 6, 2024, and August 4, 2025, reflecting significant investor dissatisfaction with the company's financial transparency.
  • Product Launch Failure: The launch of Inspire V is alleged to be a disaster due to poor demand and excess inventory among providers, leading to the company's failure to complete essential customer training and IT system setups, which undermines market confidence and future sales potential.
  • Legal Consequences: Investors have until January 5, 2026, to apply to be lead plaintiffs, indicating that the case could have significant implications for the company's future legal and financial standing, particularly regarding potential compensation.
  • Law Firm Background: Levi & Korsinsky has 20 years of experience in securities litigation, having secured hundreds of millions for aggrieved shareholders, showcasing its expertise in handling complex securities cases, which may further damage Inspire's reputation.
[object Object]
Preview
7.0
04:22 AMGlobenewswire
Inspire Medical Systems Faces Class Action for Misleading Investors, Stock Plummets 32%
  • Lawsuit Deadline Reminder: Hagens Berman law firm informs investors that the deadline to apply for lead plaintiff status in the class action against Inspire Medical Systems is January 5, 2026, urging prompt action to protect their rights.
  • Significant EPS Guidance Cut: Inspire Medical Systems slashed its 2025 EPS guidance by over 80% due to undisclosed operational issues regarding the Inspire V device launch, severely impacting the company's financial outlook.
  • Stock Price Volatility: Following the company's admission of an elongated launch timeframe, its stock plummeted 32% on August 4, 2025, translating to a $42.04 drop per share, indicating a significant loss of market confidence in management.
  • Legal Liability Investigation: Hagens Berman is investigating whether management concealed failures in Medicare claims processing software updates, which may have led to undisclosed operational challenges and investor losses.
[object Object]
Preview
7.0
01:21 AMGlobenewswire
Avantor and Others Face Class Action Lawsuits; Investors Must Note Deadlines
  • Class Action Alert: Avantor, Inc. (NYSE:AVTR) faces a class action lawsuit for failing to disclose weakened competitive positioning during the period from March 5, 2024, to October 28, 2025, with a lead plaintiff deadline of December 29, 2025, potentially impacting stock price and investor confidence.
  • Competitive Pressure Revealed: Synopsys, Inc. (NASDAQ:SNPS) is accused of not disclosing that its increased focus on AI customers negatively affected its Design IP business from December 4, 2024, to September 9, 2025, with a lead plaintiff deadline of December 30, 2025, reflecting significant market challenges.
  • Growth Prospects Questioned: CarMax, Inc. (NYSE:KMX) is alleged to have overstated growth prospects during the period from June 20, 2025, to November 5, 2025, with a lead plaintiff deadline of January 2, 2026, which may lead to diminished market confidence in future performance.
  • Demand Shortfall Issues: Inspire Medical Systems, Inc. (NYSE:INSP) faces allegations of failing to disclose poor demand for its new treatment from August 6, 2024, to August 4, 2025, with a lead plaintiff deadline of January 5, 2026, indicating significant challenges in product rollout.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Inspire Medical Systems Inc (INSP) stock price today?

The current price of INSP is 140.03 USD — it has increased 3.92 % in the last trading day.

arrow icon

What is Inspire Medical Systems Inc (INSP)'s business?

Inspire Medical Systems, Inc. is a medical technology company. The Company is focused on the development and commercialization of advanced, minimally invasive solutions for patients with obstructive sleep apnea (OSA). Its proprietary Inspire therapy is FDA, EU MDR, and PDMA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. It has developed a novel, closed-loop solution that continuously monitors a patient’s breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The Company sells its Inspire system to hospitals and ambulatory surgery centers (ASCs) in the United States (U.S.) and in select countries in Europe and Japan through a direct sales organization and sells its Inspire system in Singapore and Hong Kong through distributors. Its direct sales force engages in sales efforts and promotional activities focused on ear, nose and throat (ENT) physicians and sleep centers.

arrow icon

What is the price predicton of INSP Stock?

Wall Street analysts forecast INSP stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for INSP is 115.58 USD with a low forecast of 82.00 USD and a high forecast of 180.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Inspire Medical Systems Inc (INSP)'s revenue for the last quarter?

Inspire Medical Systems Inc revenue for the last quarter amounts to 224.50M USD, increased 10.49 % YoY.

arrow icon

What is Inspire Medical Systems Inc (INSP)'s earnings per share (EPS) for the last quarter?

Inspire Medical Systems Inc. EPS for the last quarter amounts to 0.34 USD, decreased -43.33 % YoY.

arrow icon

What changes have occurred in the market's expectations for Inspire Medical Systems Inc (INSP)'s fundamentals?

The market is revising Upward the revenue expectations for Inspire Medical Systems, Inc. (INSP) for FY2025, with the revenue forecasts being adjusted by 0.11% over the past three months. During the same period, the stock price has changed by 61.96%.
arrow icon

How many employees does Inspire Medical Systems Inc (INSP). have?

Inspire Medical Systems Inc (INSP) has 1246 emplpoyees as of December 05 2025.

arrow icon

What is Inspire Medical Systems Inc (INSP) market cap?

Today INSP has the market capitalization of 4.06B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free